Learn More-External Link
Trending at Lumira Ventures
Avalon Pharma Says AvalonRx Identifies Potent Selective Inhibitors…
Learn More-External Link
Transmolecular appoints Nicolaides as board chair
Learn More-External Link
Pharmasset’s Hepatitis C Drug Has A Promising Future
Learn More-External Link
Natus Medical to Acquire Excel-Tech Ltd.
Learn More-External Link
Pharmasset Accesses up to $30 Million of Working Capital
Learn More-External Link
Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
Learn More-External Link
Argos Therapeutics’ Scientific Founder Ralph Steinman, M.D., Receives…
Learn More-External Link
Replidyne’s Investigational Antibacterial Agent REP3123 Prevents Toxin Production…
Learn More-External Link
MAKO Surgical Announces Filing Of Registration Statement With SEC For IPO
Learn More-External Link
MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors
Learn More-External Link
Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
Learn More-External Link
Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Learn More-External Link
R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Learn More-External Link
Replidyne Pipeline Featured at 47th Annual Interscience Conference on …
Learn More-External Link